Advanced searches left 3/3

Carbon Dioxide - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 10 November 2022

* If you want to update the article please login/register

Carbon-Dioxide Flushing Versus Saline Flushing in Thoracic Endovascular Aortic Repair to Reduce Neurological Injury: A Pilot Randomised Controlled Trial

The re-lining of the thoracic aorta has been the re-lining of the thoracic aortic repair to prevent life-threatening haemorrhage and death from rupture. Stents are flushed with saline before being inserted into the patient to remove air and prevent air from reaching the brain, which can result in a condition of brain damage referred to as vascular brain infarction. Carbon-dioxide has been used extensively in cardiac surgery to remove air from the chest cavity and avoid peri-procedural cerebral air embolization. We speculate that flushing the stent-grafts with carbon-dioxide could be more effective at removing air from the stent-grafts than a traditional flush. Participants will continue transcranial doppler monitoring of the middle cerebral artery to look for cerebral air embolisation at the stent-graft deployment phase of TEVAR.

Source link: https://clinicaltrials.gov/ct2/show/NCT03886675


Comparison of Cerebral Oxymeter and End Tidal Carbondioxide Values Under Surgical Drapes in Patients With and Without Past COVID-19 Infection Undergoing Cataract Operation

Following the patients who meet the stated criteria are notified of the study, the volunteers who agreed to enroll and signed informed consent will be included in the study. After the dressing is complete, the ultrasonographic optical nerve sheath diameter measurement will be repeated immediately after the dressing is complete.

Source link: https://clinicaltrials.gov/ct2/show/NCT05571683


Randomized-Controlled Study to Evaluate the Diagnostic Quality and Safety of Automated Carbon Dioxide Angiography (ACDA) With a Robot-supported Angiography System in Combination With a CO2-Injector System in Patients With Peripheral Arterial Occlusive Disease

Since the 1970s, an intra-arterial contrast agent has been used as an intra-arterial contrast agent, particularly in patients who were hypersensitive to iodinated contrast media or whose renal function was impaired, patients were used as an intra-arterial contrast agent or whose renal function was impaired. Using the Siemens Healthineers' innovative Artis Zeego Q angiography-system and the automated CO2-injection system of Angiodroid, our research will specifically investigate the image quality and safety of carbon dioxide gas as an intra-arterial contrast agent.

Source link: https://clinicaltrials.gov/ct2/show/NCT05590182


CO2 Gap Changes Compared to Cardiac Output Changes in Response to Intravenous Volume Expansion and/or Vasopressor Therapy in Septic Shock

Increased cardiac output is one of the primary objectives of acute circulatory failure treatment [2]]. The u2206PCO2 difference in the partial pressure of carbon dioxide between mixed or central venous blood and arterial blood [1] is characterized by the difference in the difference in the partial pressure of carbon dioxide between mixed or central venous blood and arterial blood [1]. A normal CO2 gap shows that CO2 is high enough to wash out CO2 from peripheral tissues. Both the PCO2 gap or the PCO2 gap could be used to determine resuscitation therapy [6]. Aim of work The aim of the study was to investigate the importance of PCO2 gap changes in the early septic shock management, as opposed to cardiac output. Sample size calculation Based on previous research and by using G power software with a power of 0. 90 and 0. 05 alpha errors, the sample size was estimated to be 69 patients. The study was conducted in a non-randomized prospective study was conducted in Cairo university hospitals with septic shock and elevated blood lactate level > 2 mmol/L, requiring fluid resuscitation and/or vasopressor drugs infusion. Up to 30 ml/kg iv and/or by vasopressor infusion or infusion, which is closer, but the first set of measurements were taken after the introduction of invasive lines and 2nd series of measurements following the initial resuscitation when stable MAP by a fluid boluses of up to 30 ml/kg iv and/or by vasopressor infusion or after 3 hours, which is closer.

Source link: https://clinicaltrials.gov/ct2/show/NCT05578534


A Longitudinal Observational Study to Investigate the Patterns of Change in the Tidal Breathing CO2 Waveform, Measured Using the N-Tidal C Handset, in Patients With COPD Compared to Patients With Other Common Cardiorespiratory Conditions

Chronic Obstructive Pulmonary Disease is one of the most common respiratory diseases worldwide, and it is one of the top five causes of death worldwide. During normal tidal breathing, the user's Tidal Breathing CO2 waveforms were present at rest on the user's N-Tidal C handset, a sleek, hand-held wireless device, was designed to track the user's Tidal Breathing CO2 waveforms at rest. This device can be safely operated in the home environment, has a battery life of weeks, and has an isolated, disposable, breathing pathway that isolates an individual's breath from the remainder of the device, making it safe to reuse between patients after the outer casing was disinfected using a 3-stage disinfection process. The N-Tidal device has the ability to provide new insight into lung health, and early results from CRI's earlier clinical studies indicate that the TBCO2 measurements can be used to fingerprint and diagnose COPD.

Source link: https://clinicaltrials.gov/ct2/show/NCT04939558

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions